Championing Bispecific Antibodies in the VA
About this episode
This episode discusses the challenges and solutions in providing bispecific antibodies to Veterans through a collaborative model.
Bispecific antibodies (BsAbs) are an emerging and fast-developing area of immunotherapy, particularly in the treatment of hematologic malignancies. However, access to this therapy remains limited, particularly for Veterans. Administrative hurdles and challenging adverse events have slowed adoption of BsAbs in the US Department of Veterans Affairs (VA). In this episode, CANCER BUZZ speaks with Nicholas Burwick, MD, hematologist in the Puget Sound VA Health Care System, about how his VA site tackled these challenges and made BsAbs available to its patient population through a collaborative hub-and-spoke model. Guest: Nicholas Burwick, MD President, Association of VA Hematology/Oncology Hematology and Bone Marrow Transplant Puget Sound VA Health Care System "We set expectations, we came up with a plan, and we didn't have too many bispecific antibody patients at the same time. At least initially, we wanted some control." — Nicholas Burwick, MD "The collaboration among different VA centers has been something that I've come to appreciate. We have a heme malignancy group, for example, so we can compare notes, work together, and in some cases even collaborate on VA initiative proposals…
More episodes of CANCER BUZZ
- The Urology-Oncology Partnership in ADCs
- A Team Approach to ADCs in Bladder Cancer
- MDS: Low Risk Isn't No Risk
- Beyond Body Art: Restoring Wholeness Through Paramedical Tattooing
- Bridging Radiation and Oncology in SCLC Care
- Data-Driven Toxicity Management for ADCs
Explore listener stats, chart rankings, contacts and more on the CANCER BUZZ podcast page.